Psilocybin (MYCO-001) for PTSD in Veterans

Mydecine has announced they will be conducting a Phase IIa study investigating the effects of psilocybin-assisted psychotherapy in the treatment of PTSD in veterans.

The trial will use MYCO-001, Mydecine’s proprietary naturally derived psilocybin formulation.

Topic PTSD

Compound Psilocybin

Country United States of America

Visit trial

Status Planned

Results Published

Start date 02 November 2021

End date 09 November 2022

Chance of happening 72%

Phase Phase II

Design Open

Type Interventional

Generation Second

Participants 30

Sex All

Age 18- 99

Therapy Yes

Trial Details

NCT Number

Sponsors & Collaborators

Mydecine
Mydecine (Mydecine Innovations Group Inc.) is the parent organization of Mindleap, Mydecine Health Sciences, and NeuroPharm.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.